Clinical trials
Phase 2 Macular Edema trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 7 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Terminated | 8 |
| Unknown status | 5 |
| Withdrawn | 4 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Allergan | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Shahid Beheshti University of Medical Sciences | 3 |
| Boehringer Ingelheim | 2 |
| Clearside Biomedical, Inc. | 2 |
| Hospital Juarez de Mexico | 2 |
| Moorfields Eye Hospital NHS Foundation Trust | 2 |
| Novartis Pharmaceuticals | 2 |
| Rafic Hariri University Hospital | 2 |
| Unity Biotechnology, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Macular Edema | 64 |
| Diabetic Retinopathy | 16 |
| Retinal Vein Occlusion | 12 |
| Diabetes Mellitus | 10 |
| Retinal Diseases | 7 |
| Macular Degeneration | 6 |
| Uveitis | 6 |
| Edema | 3 |
| Eye Diseases | 3 |
| Retinitis Pigmentosa | 3 |
Trials
Showing 26 to 50 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.